Consequently, through the integration of adjusted p-values, log2FC, and normalized counts, we identified ADRA2B as upregulated in HD gene-positive individuals (Figure 8C), thereby emerging as a potential candidate for HD treatment. This evidence concerns the gene ADRA2B and Huntington disease.